Jop M.
- Country
- The Netherlands
- Department
- Neurology
Research Overview
- Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Personalized B Cell-Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 19 of 198 partner sites.
Specializations
Multiple Sclerosis Management
The investigator specializes in advancing therapeutic approaches for Multiple Sclerosis (MS), with particular emphasis on personalized treatment strategies and innovative drug administration protocols.
- B-cell targeted therapies
- Personalized dosing regimens
- Anti-CD20 therapy optimization
This research focus demonstrates dedication to improving treatment precision in MS care through individualized approaches.
Neurological Therapeutics
The investigator explores novel therapeutic applications in neurological conditions, including the investigation of alternative treatment modalities and drug delivery optimization.
- Extended interval dosing protocols
- Comparative treatment efficacy
- Real-life cohort studies
Their work encompasses comprehensive evaluation of treatment safety and efficacy in clinical settings.
Sleep Disorders in MS
The investigator addresses sleep quality concerns in MS patients, exploring innovative therapeutic interventions including cannabinoid-based treatments for sleep disorders.
- Sleep quality assessment
- CBD therapeutic applications
- Symptom management in MS
This research direction combines neurological care with sleep medicine to enhance patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.